Anti-OSMR Reference Antibody (vixarelimab) is a monoclonal antibody used primarily as a research tool to investigate the role of the Oncostatin M receptor (OSMR) in inflammatory and autoimmune diseases. It targets conditions involving the OSMR pathway, such as atopic dermatitis and fibrotic disorders, by blocking OSMR activity to modulate chronic inflammation and tissue damage signaling. This inhibition reduces inflammatory cytokine production and immune cell activation. As a reference standard, it enables comparison with novel anti-OSMR antibodies in preclinical models and supports the development of targeted therapies, with promising clinical outcomes observed in studies for atopic dermatitis and related conditions.